The specifics, since they change the answer: liraglutide · ten weeks · 40 °C.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
What is actually going on here, physically?
ten weeks is 70 days, which at 40 °C is on the order of 792 refrigerated days. 40 °C is 35 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 11 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. In solution the routes that matter are hydrolysis of the backbone, deamidation at Asn, and physical association — the first two cost content, the third costs neither until it precipitates. Over 70 days at 40 °C you should expect all three to have moved, and a purity figure to have noticed only some of them. Reconstituted material has no certificate; the one in the box describes the powder.
The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
At dilute concentrations, suspect adsorption before you suspect chemistry.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.
Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
Nothing here is medical advice, and research-use compounds are not approved for human use.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
Sequence determines which pathways apply, so general statements are general.
Cold, dry, dark, still. Those four words cover most of the mitigation.
The relevant detail is that asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
edited 3 Jul 2025 by fill_volume — added the citation requested in comments
Mechanically, this is answerable from the chemistry rather than from anecdote, which is unusual and welcome.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.
The caveat is that "within specification" and "unchanged" are different claims. A vial can lose a few per cent of content and still be usable for its purpose while no longer matching its certificate.
Sequence decides which pathways are even available. Check the residues.
edited 18 May 2025 by one_ml_bac — corrected a unit error in the worked example
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.